Clinical trials: Nonalcoholic Fatty Liver
Nonalcoholic Steatohepatitis
Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)
This Phase 2, double-blind, randomized, placebo-controlled, multicenter study, with an open-label long-term safety extension (LTSE), will evaluate the effect of Obeticholic Acid, and the subsequent addition of statin therapy, on…
- Trial name
- CONTROL (NCT02633956)
- Testing
- Obeticholic Acid, Atorvastatin
- Where
- 22 sites in United States
- Volunteers
- 84 people
- Sponsor
- Intercept Pharmaceuticals
Fatty Liver
Weight Management in Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is one of the most common chronic liver diseases. The cause of NASH is not completely understood and currently there is no effective treatment for this disease.
- Trial name
- NCT00266019
- Testing
- Weight Management (diet, exercise, and behavior modification)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease
Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease
The worldwide impact of obesity suggests an urgent need for solutions to decrease its burden on modern society. It has been generally understood that obesity is caused by a simple imbalance in the intake of energy in the form of…
- Trial name
- NCT04594954
- Testing
- Diet, FMT, Physical Activity
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Nonalcoholic Steatohepatitis
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
A Randomized, Controlled, Double-blind, Parallel Group, Single Center Phase 2 Clinical Trial to Evaluate Multiple Non-Invasive Liver Fibrosis Imaging Methods in the Assessment of the Efficacy of GR-MD-02 for the Treatment of…
- Trial name
- NASH-FX (NCT02421094)
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Galectin Therapeutics Inc.
Fatty Liver Disease, Chronic Glomerular Disease
Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease
The association of metabolic associated fatty liver disease in patients with chronic glomerular disease
- Trial name
- NCT06691529
- Volunteers
- 500 people
- Sponsor
- Assiut University
Covid19, NAFLD
COVID-19 and Nonalcoholic Fatty Liver Disease
COVID-19 is currently the leading public health problem, associated with a high risk of complications and death in risk groups of patients.
- Trial name
- CovidFAT (NCT04982328)
- Testing
- Th17 cytokine profile, Screening for the components of metabolic syndrome, Evaluation of the degree of steatosis
- Where
- Croatia
- Volunteers
- 120 people
- Sponsor
- University Hospital for Infectious Diseases, Croatia
NASH, HCC
Evaluation of Risk of hEpatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common solid cancer and the second cause of cancer-related mortality worldwide.
- Conditions
- NASH, HCC, Genetic Predisposition
- Trial name
- PERSPECTIVE (NCT06523179)
- Testing
- quantify the impact of genetic risk factors
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Non-alcoholic Steatohepatitis
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
- Trial name
- NCT02912260
- Testing
- MGL-3196
- Where
- 26 sites in United States
- Volunteers
- 125 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Obesity, Morbid, Obesity
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction
A recent review demonstrated that Non-alcoholic fatty liver disease (NAFLD) affects 10-35% of the adult population worldwide, with the prevalence approaching 85-100% in obese populations.
- Conditions
- Obesity, Morbid, Obesity, NAFLD, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT03132662
- Testing
- Omega-3, Very Low Calorie Diet
- Volunteers
- 60 people
- Sponsor
- McMaster University
Fatty Liver, Fatty Liver, Alcoholic
Fatty Liver Disease Collaborative Research in China
A multi-center, prospective cohort study on the natural history of fatty liver disease in China
- Conditions
- Fatty Liver, Fatty Liver, Alcoholic, Non-alcoholic Fatty Liver Disease
- Trial name
- FLDCR (NCT02391168)
- Where
- 6 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Fatty Liver and Alcoholic Liver Disease Study Group, China
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Non-Alcoholic Fatty Liver Disease
Effect of Omega-3 PUFA Supplementation in NAFLD Patients
The purpose of this study is to determine whether dietary supplementation with omega-3 polyunsaturated fatty acids will decrease the amount of fat in liver.
- Trial name
- NCT00230113
- Testing
- Fish oil, Safflower oil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Coronary Disease, Coronary Arteriosclerosis
Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease
Diet can play a key role in atherosclerosis and coronary heart disease (CHD), but little interventional data exists, and the mediators of possible anti-atherosclerotic effects of diet are unclear.
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Myocardial Infarction, Chronic Coronary Syndrome
- Trial name
- NORDHEART (NCT06701968)
- Testing
- Healthy Nordic Diet, Usual Care
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University
Fatty Liver Disease, Nonalcoholic
Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFF
Ultrasound Derived Fat Fraction (UDFF) Evaluation of Metabolic Related Fatty Liver Disease (MAFLD) in obesity Patients Metabolic fatty liver disease (MAFLD), formerly known as Nonalcoholic Fatty Liver Disease (NAFLD), is the most…
- Trial name
- NCT06097338
- Testing
- bariatric surgery (BS)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Liver Diseases
Identification of Hepatic Fibrosis Using 4D-MRI
To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a…
- Trial name
- 4D-MRI Liver (NCT05385237)
- Testing
- 4D-MRI
- Where
- 2 sites in Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
NASH - Nonalcoholic Steatohepatitis
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of fluconazole or quinidine on the pharmacokinetics and safety of EDP-305 in healthy human…
- Trial name
- NCT03610945
- Testing
- Fluconazole, Quinidine, EDP-305
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
NAFLD, Diabetes Mellitus
Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases
The goal of this cross-sectional observational study is to to perform a thorough characterization of the quantitative and qualitative differences in peripheral blood cells, and circulating factors (proteins, metabolites, lipids…
- Conditions
- NAFLD, Diabetes Mellitus, Obesity
- Trial name
- PERIMED (NCT06396871)
- Testing
- Oral glucose tolerance test, Liver Ultrasound, Fibroscan of the Liver
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- Technische Universität Dresden
Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial to assess the efficacy and safety of weekly subcutaneous DR10624 injection in adult patients with severe hypertriglyceridemia (sHTG).
- Trial name
- NCT07693777
- Testing
- DR10624 Injection
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
NASH, NAFLD
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
The purpose of the KETONASH study is to evaluate, in patients with metabolic-associated fatty liver disease (MAFLD) with non-alcoholic steatohepatitis (NASH) and significant liver fibrosis, the effect of a very low-calorie…
- Conditions
- NASH, NAFLD, Obesity, Liver Fibrosis
- Trial name
- KETONASH (NCT06308757)
- Testing
- Very-low-calorie ketogenic diet (VLCKD) with meal replacements, Mediterranean low-calorie diet (LCD)
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- University of Bologna
Type 2 Diabetes, Coronary Heart Disease
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)
PREMAP invites residents of the Eloisa region (South Savo, Finland) turning 45, 50, or 55 years of age in 2026 to undergo a blood-based NMR metabolomics risk assessment for five interlinked cardio-renal-metabolic conditions (type…
- Conditions
- Type 2 Diabetes, Coronary Heart Disease, Myocardial Infarction, Cerebrovascular Disease
- Trial name
- PREMAP (NCT07820800)
- Testing
- Digital health interventions
- Where
- Finland
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.